Holen Sie sich die Stockscreener-App
151.53
1.66%
2.47
Handel nachbörslich:
151.53
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt RVTY?
Forum
Prognose
Aktiensplit
Dividendenhistorie
Schlusskurs vom Vortag:
$149.06
Offen:
$149.94
24-Stunden-Volumen:
1.24M
Relative Volume:
0.71
Marktkapitalisierung:
$16.91B
Einnahmen:
$2.90B
Nettoeinkommen (Verlust:
$239.11M
KGV:
71.83
EPS:
2.1097
Netto-Cashflow:
$492.62M
1W Leistung:
+0.28%
1M Leistung:
+15.72%
6M Leistung:
+70.37%
1J Leistung:
+65.68%
1-Tages-Spanne:
$148.55
$153.38
1-Wochen-Bereich:
$148.12
$158.28
52-Wochen-Spanne:
$81.22
$158.28
Revvity Inc Stock (RVTY) Company Profile
Firmenname
Revvity Inc
Sektor
Branche
Telefon
781-663-6900
Adresse
77 4TH AVENUE, WALTHAM
Compare RVTY vs TMO, DHR, NTRA, A, IQV
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
RVTY
Revvity Inc
|
151.53 | 16.86B | 2.90B | 239.11M | 492.62M | 2.1097 |
TMO
Thermo Fisher Scientific Inc
|
654.80 | 241.26B | 45.20B | 6.87B | 6.75B | 18.19 |
DHR
Danaher Corp
|
214.06 | 150.48B | 24.78B | 3.68B | 5.29B | 5.1743 |
NTRA
Natera Inc
|
410.35 | 59.47B | 2.50B | -226.32M | 71.51M | -1.6412 |
A
Agilent Technologies Inc
|
167.78 | 48.71B | 7.23B | 1.41B | 1.09B | 4.979 |
IQV
Iqvia Holdings Inc
|
258.21 | 44.50B | 16.63B | 1.39B | 2.12B | 8.0674 |
Revvity Inc Stock (RVTY) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-04-14 | Herabstufung | Barclays | Overweight → Equal Weight |
| 2025-12-15 | Herabstufung | BofA Securities | Buy → Neutral |
| 2025-12-09 | Eingeleitet | Goldman | Neutral |
| 2025-10-16 | Eingeleitet | Guggenheim | Neutral |
| 2025-05-01 | Hochstufung | UBS | Neutral → Buy |
| 2025-01-10 | Herabstufung | Bernstein | Outperform → Mkt Perform |
| 2024-12-13 | Hochstufung | BofA Securities | Neutral → Buy |
| 2024-10-15 | Hochstufung | Barclays | Equal Weight → Overweight |
| 2024-08-28 | Eingeleitet | Wells Fargo | Equal Weight |
| 2024-07-08 | Eingeleitet | Leerink Partners | Outperform |
| 2024-06-03 | Fortgesetzt | Jefferies | Hold |
| 2024-01-16 | Herabstufung | UBS | Buy → Neutral |
| 2024-01-04 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2023-12-19 | Eingeleitet | Wells Fargo | Equal Weight |
| 2023-12-13 | Eingeleitet | Wolfe Research | Peer Perform |
| 2023-09-28 | Eingeleitet | Bernstein | Outperform |
| 2023-07-19 | Eingeleitet | Raymond James | Outperform |
| 2023-05-23 | Fortgesetzt | Goldman | Buy |
Alle ansehen
Revvity Inc Aktie (RVTY) Neueste Nachrichten
Form 144 REVVITY For: 1 October By Investing.com - Investing.com Canada
An officer proposes selling 84 Revvity (NYSE: RVTY) shares valued at $13.1K. - Stock Titan
Revvity, Inc. (RVTY) Stock Forecasts - Yahoo Finance
North America Non-Viral Transfection Reagents Market Forecast to 2035 | Cell and Gene Therapy Demand Drives 8.5% CAGR and a USD 0.70 Billion Opportunity - GlobeNewswire Inc.
Revvity, Inc. (RVTY) Stock Price, News, Quote & History - Yahoo! Finance Canada
Cloud Fails To Upend Revvity's $4.5M Fee, Contract Win - Law360
Revvity Inc. stock outperforms competitors on strong trading day - MarketWatch
Here's Why You Should Retain Revvity Stock in Your Portfolio for Now - TradingView
Revvity (RVTY): Buy, Sell, or Hold Post Q2 Earnings? - TradingView
Revvity, Inc. (RVTY) stock price, news, quote and history - uk.finance.yahoo.com
Revvity stock last trades at USD 150.00 on September 28, 2026 - AD HOC NEWS
Form 144 REVVITY For: 27 September By Investing.com - Investing.com UK
Revvity declares $0.07 quarterly dividend for shareholders - scanx.trade
PKI4882935 Bond Profile: Coupon and Redemption - TradingView
Revvity options flow shows 156:1 call-to-put ratio ahead of Nov. 2026 expiry - Investing.com
Revvity, Inc. (RVTY) latest stock news and headlines – Yahoo Finance - Yahoo Finance Singapore
RVTY Launches New Kit in Europe for Newborn Type 1 Diabetes Detection - Yahoo Finance
New Products: Qiagen, Helix, Countable Labs, AtlasBio, Revvity, Agilent - GenomeWeb
Revvity Q2FY26 Results: Organic growth hits 3%, adjusted EPS $1.41 - scanx.trade
Full Transcript: Revvity Q2 2026 Earnings Call - Benzinga
Revvity (RVTY) Short Interest & Short Float | Updated Sep 2026 $RVTY - MarketBeat
Revvity stock gains 5.2 percent ahead of the open - AD HOC NEWS
Revvity Inc (RVTY) Shares Surge 6.0% -- What GF Score of 78 Tells Investors - GuruFocus
Here’s How Much You Would Have Made Owning Revvity Stock In The Last 15 Years - Benzinga
Revvity shares rise as analyst target hike adds to momentum from deal and guidance - Quiver Quantitative
Revvity Inc stock hits 52-week high at 149.72 USD By Investing.com - Investing.com India
Revvity Inc stock hits 52-week high at 149.72 USD - Investing.com
Top Midday Stories: Oracle's Data Center Delay; People Withdraws MGM Offer; Revvity's New Diabetes Test - Yahoo Finance
Revvity, Inc. Launches GSP® T1D 3plex Kit For Early Detection Of Type 1 Diabetes - marketscreener.com
Revvity Shares Rise on Launch of Child Type 1 Diabetes Screening Test - marketscreener.com
RVTY Looks 20.9% Overvalued on GF Value™ as Insider Selling Pers - gurufocus.com
Revvity launches type 1 diabetes screening kit in Europe - Investing.com
Revvity launches type 1 diabetes screening kit in Europe By Investing.com - Investing.com Canada
Revvity Launches IVDR-Certified Solution for Early Detection of Type 1 Diabetes - Business Wire
Leerink Partners Adjusts Revvity Price Target to $160 From $145, Maintains Outperform Rating - marketscreener.com
Insider Maxwell Krakowiak Sells 1,631 Shares of Revvity Inc (RVT - GuruFocus
Is Revvity Stock Outperforming the Dow? - webull.com
Revvity CFO Maxwell Krakowiak sells $235,728 in RVTY stock - Investing.com India
Revvity CFO Maxwell Krakowiak sells $235,728 in RVTY stock By Investing.com - Investing.com Australia
Form 4 Revvity Inc For: 23 September - Investing.com India
After selling 1,631 shares, Revvity (RVTY) CFO holds 14,781 shares - Stock Titan
Understanding Momentum Shifts in (RVTY) - news.stocktradersdaily.com
Why Revvity (RVTY) Is Getting Attention Today - Yahoo Finance
Revvity stock holds near USD 143 after target hike - AD HOC NEWS
Revvity stock heads into the open after a Goldman target hike - AD HOC NEWS
Revvity Inc. stock gains on Goldman Sachs price target hike - AD HOC NEWS
Revvity (NYSE: RVTY) shareholder may sell stock under Rule 144 - Stock Titan
Goldman Sachs Adjusts Price Target on Revvity to $140 From $100, Keeps Neutral Rating - Yahoo Finance
Revvity, Inc. (RVTY) Stock Analysis: A Healthcare Diagnostics Giant with a Cautious Analyst Outlook - DirectorsTalk Interviews
Revvity Inc. stock gains on Human Cell Design deal and recent rally - AD HOC NEWS
Senior Vice President of Global Operations Tajinder Vohra Sold A Bunch Of Shares In Revvity - simplywall.st
Finanzdaten der Revvity Inc-Aktie (RVTY)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.97%
0.08%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):